The first category are designed to enhance endogenous anti-tumor immunity and include vaccines [1], immune agonists like anti-CD40 [2], and inhibitors of immune checkpoints such as anti-CTLA-4 [3] and anti-PD-1/PD-L1 [4]. This evidence concerns the gene CD274 and neoplasm.